{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:07:11Z","timestamp":1774552031417,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an immune-mediated demyelinating disorder of the central nervous system. It has a higher incidence in children than in adults, carries a relatively high risk of relapse with unclear mechanisms, and significantly impacts patient prognosis. This study aimed to investigate the clinical characteristics of MOGAD and identify independent risk factors for relapse, to provide a basis for early intervention and individualized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 108 children diagnosed with MOGAD at the Children\u2019s Hospital of Nanjing Medical University between January 2020 and June 2024 were retrospectively enrolled. Clinical, laboratory, and radiological data were collected. Univariate analysis and multivariate logistic regression models were used to screen for risk factors associated with relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up time was 37\u202fmonths, with a relapse rate of 30.6%. The proportion of patients presenting with seizures (54.5% vs. 20.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and limb weakness (27.3% vs. 9.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.018) at onset was significantly higher in the relapse group compared to the monophasic group. The most common initial clinical phenotype was acute disseminated encephalomyelitis (ADEM) type (38.9%), while optic neuritis (ON) type became predominant at relapse (48.9%). Multivariate analysis identified seizures (OR\u202f=\u202f7.155, 95% CI: 2.265\u201322.604,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and limb weakness (OR\u202f=\u202f5.157, 95% CI: 1.322\u201320.117,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.018) as independent risk factors for relapse, whereas a normal brain MRI (OR\u202f=\u202f0.186, 95% CI: 0.035\u20130.985,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.048) was a protective factor. The relapse group had a higher proportion of patients with high serum MOG antibody titers (\u22651:100) (54.5% vs. 32.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.027) and elevated cerebrospinal fluid cell counts (&amp;gt;30\u202f\u00d7\u202f10\n                      <jats:sup>6<\/jats:sup>\n                      \/L) (66.7% vs. 44.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.03). Patients receiving oral corticosteroids for \u22656\u202fmonths during the remission phase had a significantly lower relapse rate (42.4% vs. 65.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In pediatric MOGAD, the ADEM phenotype is most common at onset. Seizures and limb weakness at initial presentation are independent risk factors for relapse in children with MOGAD, while a normal brain MRI suggests a lower relapse risk. Prolonging the corticosteroid treatment course during remission (\u22656\u202fmonths) may help reduce the relapse risk. Enhanced follow-up and individualized treatment should be considered for children with high-risk factors. These findings may help clinicians identify high-risk patients and tailor long-term immunosuppressive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1790844","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:34:00Z","timestamp":1774550040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of risk factors for relapse in pediatric MOG antibody-associated disease: a single-center retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaohui","family":"Min","sequence":"first","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohuan","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooraynee Bibi Needah","family":"Ginowree","sequence":"additional","affiliation":[{"name":"Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jalal","family":"Ud Din","sequence":"additional","affiliation":[{"name":"Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3345\/cep.2019.01305","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options","volume":"64","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00234-007-0216-2","article-title":"Idiopathic inflammatory-demyelinating diseases of the central nervous system","volume":"49","author":"Ca\u00f1ellas","year":"2007","journal-title":"Neuroradiology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1212\/con.0000000000001127","article-title":"Myelin oligodendrocyte glycoprotein-associated disorders","volume":"28","author":"Longbrake","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1188323","DOI":"10.3389\/fneur.2023.1188323","article-title":"Phenotypic characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in children: a single-center, retrospective study","volume":"14","author":"Hua","year":"2023","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fneur.2019.00415","article-title":"Seizure and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis in a retrospective cohort of Chinese patients","volume":"10","author":"Zhong","year":"2019","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jnnp-2020-324422","article-title":"Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany","volume":"92","author":"Liu","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaneurol.2025.1774","article-title":"Meningitis as an attack phenotype of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"82","author":"Aboseif","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1790844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:34:01Z","timestamp":1774550041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1790844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":24,"alternative-id":["10.3389\/fneur.2026.1790844"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1790844","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1790844"}}